Source comparison
CJC-1295 Dose Response Research: Dosing Protocol Comparison
Low-dose sustained 30–40 mcg/kg Every 7 days 2–3× baseline 5–7 days Minimal Ideal for older subjects or those with low baseline IGF-1. Avoids overstimulation while maintaining steady-state elevation Moderate-dose optimal 60–80 mcg/kg 4–5× baseline 7–9 days Low
This comparison does not assign a generated winner or score.
- Low-dose sustained
- 30–40 mcg/kg
- Every 7 days
- 2–3× baseline
- 5–7 days
- Minimal
- Ideal for older subjects or those with low baseline IGF-1. Avoids overstimulation while maintaining steady-state elevation
- Moderate-dose optimal
- 60–80 mcg/kg
- 4–5× baseline
- 7–9 days
- Low
- Gold standard in cjc-1295 dose response research. Maximizes efficacy without exceeding receptor capacity
- High-dose threshold
- 100 mcg/kg
- Every 7–10 days
- 5–6× baseline
- Moderate
- Approaches saturation ceiling. No additional benefit beyond 60–80 mcg/kg for most subjects
- Excessive supradose
- 150–200+ mcg/kg
- Twice weekly
- 5–6× baseline (no increase vs 100 mcg/kg)
- Variable, inconsistent
- High
- Exceeds receptor capacity. Produces adverse effects (hyperglycemia, edema) without proportional GH increase
- Microdose frequent
- 10–20 mcg/kg
- Every 3–4 days
- 1.5–2× baseline
- 2–3 days
- Subtherapeutic for most applications. Fails to sustain IGF-1 elevation between doses